CLINICAL_TRIALS
trial_result
· 2025-11-26
Clinical Trial Update: BO-112 With Pembrolizumab in Unresectable Malignant Melanoma [Phase 2]
Summary
Phase 2 trial of BO-112 in combination with pembrolizumab for unresectable malignant melanoma has completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Highlight Therapeutics | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2025-11-26